首页 / 院系成果 / 成果详情页

Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis 期刊论文

编号：

b0b53c61-1866-47ba-9168-af11eb1c6da4
作者：

Kan, ShunLi#^[1]Li, Yan(李燕)#^[1]Ning, GuangZhi(宁广智)#^[1]Yuan, ZhiFang^[2];Chen, LingXiao(陈凌霄)^[1]Bi, MingChao(毕明超)^[3]Sun, JingCheng(孙景城)^[1]Feng, ShiQing(冯世庆)*^[1]
语种：

英文
期刊：

PLOS ONE ISSN：1932-6203 2016 年 11 卷 6 期 ; JUN 13
收录：
摘要：

Objective
Tanezumab is a new therapeutic intervention for patients with osteoarthritis (OA) of the knee. We performed the present meta-analysis to appraise the efficacy and safety of tanezumab for patients with knee OA.
Methods
We systematically searched randomized controlled trials from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The primary outcomes were mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, the WOMAC physical function and patient"s global assessment (PGA). Outcomes were reported as the standard mean difference (SMD) or relative risk (RR) with 95% confidence interval (CI). We assessed the pooled data using a random-effects model.
Results
Of the identified studies, four were eligible and were included in this meta-analysis (N = 1839 participants). Compared with the placebo groups, tanezumab yielded a significant reduction in mean change in the WOMAC pain (SMD = 0.51, 95% CI 0.34 to 0.69, P<0.00001), the WOMAC physical function (SMD = 0.56, 95% CI 0.38 to 0.74, P<0.00001) and PGA (SMD = 0.34, 95% CI 0.22 to 0.47, P<0.00001). There was no significant difference in serious adverse events (RR = 1.06, 95% CI 0.59 to 1.92, P = 0.84) between the tanezumab and placebo groups. Tanezumab significantly increased discontinuations due to adverse events (RR = 2.89, 95% CI 1.59 to 5.26, P = 0.0005), abnormal peripheral sensations (RR = 3.14, 95% CI 2.12 to 4.66, P<0.00001), and peripheral neuropathy (RR = 6.05, 95% CI 2.32 to 15.81, P = 0.0002).
Conclusion
Tanezumab can alleviate pain and improve function for patients with OA of the knee. However, considering the limited number of studies, this conclusion should be interpreted cautiously and more clinical randomized controlled trials are needed to verify the efficacy and safety of tanezumab for OA of the knee.
推荐引用方式
GB/T 7714：

Kan Shun-Li,Li Yan,Ning Guang-Zhi, et al. Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis [J].PLOS ONE,2016,11(6).
APA：

Kan Shun-Li,Li Yan,Ning Guang-Zhi,Yuan Zhi-Fang,&Feng Shi-Qing.(2016).Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis .PLOS ONE,11(6).
MLA：

Kan Shun-Li, et al. "Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis" .PLOS ONE 11,6(2016).
入库时间：

12/16/2019 3:18:32 PM
更新时间：

12/16/2019 3:18:32 PM
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：9  下载次数：0

分享到：

浏览次数：9

下载次数：0

打印次数：0